NEOG Quote, Financials, Valuation and Earnings

Amgen, Inc. has a net margin of 17.37% compared to Neogen Corp.'s net margin of 33.55%. Neogen Corp.'s return on equity of -41.21% beat Amgen, Inc.'s return on equity of 95.55%.

Neogen Corp. has a consensus price target of $8.17, signalling upside risk potential of 37.72%. On the other hand Amgen, Inc. has an analysts' consensus of $324.25 which suggests that it could fall by -4.68%. Given that Neogen Corp. has higher upside potential than Amgen, Inc., analysts believe Neogen Corp. is more attractive than Amgen, Inc..

Neogen Corp. has a beta of 1.986, which suggesting that the stock is 98.621% more volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.

Neogen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.8% to investors and pays a quarterly dividend of $2.38 per share. Neogen Corp. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.

Neogen Corp. quarterly revenues are $209.2M, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Neogen Corp.'s net income of $36.3M is lower than Amgen, Inc.'s net income of $3.2B. Notably, Neogen Corp.'s price-to-earnings ratio is 2,124.15x while Amgen, Inc.'s PE ratio is 26.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen Corp. is 1.45x versus 5.13x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 17.37% compared to Neogen Corp.'s net margin of 21.47%. Neogen Corp.'s return on equity of -41.21% beat Johnson & Johnson's return on equity of 33.27%.

Neogen Corp. has a consensus price target of $8.17, signalling upside risk potential of 37.72%. On the other hand Johnson & Johnson has an analysts' consensus of $202.54 which suggests that it could grow by 0.03%. Given that Neogen Corp. has higher upside potential than Johnson & Johnson, analysts believe Neogen Corp. is more attractive than Johnson & Johnson.

Neogen Corp. has a beta of 1.986, which suggesting that the stock is 98.621% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Neogen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.54% to investors and pays a quarterly dividend of $1.30 per share. Neogen Corp. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Neogen Corp. quarterly revenues are $209.2M, which are smaller than Johnson & Johnson quarterly revenues of $24B. Neogen Corp.'s net income of $36.3M is lower than Johnson & Johnson's net income of $5.2B. Notably, Neogen Corp.'s price-to-earnings ratio is 2,124.15x while Johnson & Johnson's PE ratio is 19.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen Corp. is 1.45x versus 5.33x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Myriad Genetics, Inc. has a net margin of 17.37% compared to Neogen Corp.'s net margin of -13.32%. Neogen Corp.'s return on equity of -41.21% beat Myriad Genetics, Inc.'s return on equity of -69.09%.

Neogen Corp. has a consensus price target of $8.17, signalling upside risk potential of 37.72%. On the other hand Myriad Genetics, Inc. has an analysts' consensus of $8.52 which suggests that it could grow by 16.24%. Given that Neogen Corp. has higher upside potential than Myriad Genetics, Inc., analysts believe Neogen Corp. is more attractive than Myriad Genetics, Inc..

Neogen Corp. has a beta of 1.986, which suggesting that the stock is 98.621% more volatile than S&P 500. In comparison Myriad Genetics, Inc. has a beta of 1.811, suggesting its more volatile than the S&P 500 by 81.148%.

Neogen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myriad Genetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neogen Corp. pays -- of its earnings as a dividend. Myriad Genetics, Inc. pays out -- of its earnings as a dividend.

Neogen Corp. quarterly revenues are $209.2M, which are larger than Myriad Genetics, Inc. quarterly revenues of $205.7M. Neogen Corp.'s net income of $36.3M is higher than Myriad Genetics, Inc.'s net income of -$27.4M. Notably, Neogen Corp.'s price-to-earnings ratio is 2,124.15x while Myriad Genetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen Corp. is 1.45x versus 0.82x for Myriad Genetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Replimune Group, Inc. has a net margin of 17.37% compared to Neogen Corp.'s net margin of --. Neogen Corp.'s return on equity of -41.21% beat Replimune Group, Inc.'s return on equity of -82.53%.

Neogen Corp. has a consensus price target of $8.17, signalling upside risk potential of 37.72%. On the other hand Replimune Group, Inc. has an analysts' consensus of $12.57 which suggests that it could grow by 19.39%. Given that Neogen Corp. has higher upside potential than Replimune Group, Inc., analysts believe Neogen Corp. is more attractive than Replimune Group, Inc..

Neogen Corp. has a beta of 1.986, which suggesting that the stock is 98.621% more volatile than S&P 500. In comparison Replimune Group, Inc. has a beta of 0.659, suggesting its less volatile than the S&P 500 by 34.125%.

Neogen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Replimune Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neogen Corp. pays -- of its earnings as a dividend. Replimune Group, Inc. pays out -- of its earnings as a dividend.

Neogen Corp. quarterly revenues are $209.2M, which are larger than Replimune Group, Inc. quarterly revenues of --. Neogen Corp.'s net income of $36.3M is higher than Replimune Group, Inc.'s net income of -$83.1M. Notably, Neogen Corp.'s price-to-earnings ratio is 2,124.15x while Replimune Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen Corp. is 1.45x versus -- for Replimune Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.